IGF1 rs5742612多态性与代谢功能障碍相关脂肪性肝病发病风险的关联研究
Association between IGF1 rs5742612 Polymorphism and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease
DOI: 10.12677/acm.2025.152520, PDF,   
作者: 林于蕾:青岛大学青岛市市立医院感染性疾病科,山东 青岛;赵真真*:青岛大学青岛市市立医院临床研究中心,山东 青岛
关键词: 非酒精性脂肪性肝病代谢功能障碍相关脂肪性肝病IGF1基因多态性Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction-Associated Steatotic Liver Disease IGF1 Gene Polymorphisms
摘要: 目的:研究IGF1 rs5742612位点的基因多态性与中国青岛地区汉族人群中MASLD发病风险之间的相关性。方法:纳入2022年12月到2023年12月于青岛市市立医院就诊的确诊为MASLD的中国汉族患者205人作为研究的病例组;同时纳入130名健康体检者作为对照组。收集纳入研究的患者的基本临床信息,进行生化指标的临床检测及基因组DNA的提取和IGF1 rs5742612位点基因型测定。利用χ2检验来检验两组间基因型频率和等位基因频率是否存在差异。基于显性和隐性模型,采用Logistic回归分析基因型和等位基因与疾病发生风险的关联。结果:IGF1 rs5742612位点基因型频率(χ2 = 0.286, P = 0.867)和等位基因频率(χ2 = 0.083, P = 0.773)在两组之间的分布无统计学差异。显性和隐性模型均提示该位点与MASLD之间关联不存在统计学意义(P均 < 0.05)。不同等位基因携带者基本信息及生化指标间无统计学差异(P均 > 0.05)。结论:IGF1 rs5742612多态性与MASLD发病无显著相关性。
Abstract: Objective: To investigate the correlation between genetic polymorphisms at the IGF1 rs5742612 locus and the risk of developing MASLD in the Han Chinese population in Qingdao, China. Methods: A total of 205 Chinese Han patients diagnosed with MASLD who attended Qingdao Municipal Hospital from December 2022 to December 2023 were included as the case group of the study;130 healthy medical check-ups were also included as the control group. The basic clinical information of the patients included in the study was collected, and clinical tests of biochemical indexes as well as genomic DNA extraction and genotyping at the IGF1 rs5742612 locus were performed. The χ2 test was used to test whether there were differences in genotype frequencies and allele frequencies between the two groups. Based on the dominant and recessive models, logistic regression was used to analyse the association between genotype and allele and the risk of disease occurrence. Results: The distribution of genotype frequencies (χ2 = 0.286, P = 0.867) and allele frequencies (χ2 = 0.083, P = 0.773) at the IGF1 rs5742612 locus were not statistically different between the two groups. Both dominant and recessive models suggested that the association between this locus and MASLD was not statistically significant (both P < 0.05). There was no statistical difference between the basic information and biochemical indexes of different allele carriers (all P > 0.05). Conclusion: There was no significant correlation between IGF1 rs5742612 polymorphism and the development of MASLD.
文章引用:林于蕾, 赵真真. IGF1 rs5742612多态性与代谢功能障碍相关脂肪性肝病发病风险的关联研究[J]. 临床医学进展, 2025, 15(2): 1636-1645. https://doi.org/10.12677/acm.2025.152520

参考文献

[1] Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64. [Google Scholar] [CrossRef] [PubMed]
[2] Chan, W., Chuah, K., Rajaram, R.B., Lim, L., Ratnasingam, J. and Vethakkan, S.R. (2023) Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Journal of Obesity & Metabolic Syndrome, 32, 197-213. [Google Scholar] [CrossRef] [PubMed]
[3] Marušić, M., Paić, M., Knobloch, M. and Liberati Pršo, A. (2021) NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Canadian Journal of Gastroenterology and Hepatology, 2021, Article ID: 6613827. [Google Scholar] [CrossRef] [PubMed]
[4] Bril, F., Sanyal, A. and Cusi, K. (2023) Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 27, 187-210. [Google Scholar] [CrossRef] [PubMed]
[5] Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., et al. (2011) Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLOS Genetics, 7, e1001324.
[6] Parisinos, C.A., Wilman, H.R., Thomas, E.L., Kelly, M., Nicholls, R.C., McGonigle, J., et al. (2020) Genome-Wide and Mendelian Randomisation Studies of Liver MRI Yield Insights into the Pathogenesis of Steatohepatitis. Journal of Hepatology, 73, 241-251. [Google Scholar] [CrossRef] [PubMed]
[7] Mancina, R.M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., et al. (2016) The MBOAT7-TMC4 Variant Rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 150, 1219-1230.e6. [Google Scholar] [CrossRef] [PubMed]
[8] Thangapandi, V.R., Knittelfelder, O., Brosch, M., Patsenker, E., Vvedenskaya, O., Buch, S., et al. (2020) Loss of Hepatic Mboat7 Leads to Liver Fibrosis. Gut, 70, 940-950. [Google Scholar] [CrossRef] [PubMed]
[9] Abul-Husn, N.S., Cheng, X., Li, A.H., Xin, Y., Schurmann, C., Stevis, P., et al. (2018) A Protein-Truncating hsd17b13 Variant and Protection from Chronic Liver Disease. New England Journal of Medicine, 378, 1096-1106. [Google Scholar] [CrossRef] [PubMed]
[10] Abate, N., Carulli, L., Cabo-Chan, A., Chandalia, M., Snell, P.G. and Grundy, S.M. (2003) Genetic Polymorphism PC-1 K121Q and Ethnic Susceptibility to Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism, 88, 5927-5934. [Google Scholar] [CrossRef] [PubMed]
[11] Duan, Y., Ke, X., Wu, H., Yao, S., Shi, W., Han, J., et al. (2023) Multi‐Tissue Transcriptome‐Wide Association Study Reveals Susceptibility Genes and Drug Targets for Insulin Resistance‐Relevant Phenotypes. Diabetes, Obesity and Metabolism, 26, 135-147. [Google Scholar] [CrossRef] [PubMed]
[12] Tricoli, J.V., Rall, L.B., Scott, J., Bell, G.I. and Shows, T.B. (1984) Localization of Insulin-Like Growth Factor Genes to Human Chromosomes 11 and 12. Nature, 310, 784-786. [Google Scholar] [CrossRef] [PubMed]
[13] Shimatsu, A. and Rotwein, P. (1987) Mosaic Evolution of the Insulin-Like Growth Factors. Organization, Sequence, and Expression of the Rat Insulin-Like Growth Factor I Gene. Journal of Biological Chemistry, 262, 7894-7900. [Google Scholar] [CrossRef] [PubMed]
[14] Stanley, T.L., Fourman, L.T., Zheng, I., McClure, C.M., Feldpausch, M.N., Torriani, M., et al. (2020) Relationship of IGF-1 and Igf-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism, 106, e520-e533. [Google Scholar] [CrossRef] [PubMed]
[15] Petäjä, E.M., Zhou, Y., Havana, M., Hakkarainen, A., Lundbom, N., Ihalainen, J., et al. (2016) Phosphorylated IGFBP-1 as a Non-Invasive Predictor of Liver Fat in NAFLD. Scientific Reports, 6, Article No. 24740. [Google Scholar] [CrossRef] [PubMed]
[16] Guan, M., Wang, H., Fang, H., Zhang, C., Gao, S. and Zou, Y. (2016) Association between IGF1 Gene Single Nucleotide Polymorphism (rs5742612) and Adolescent Idiopathic Scoliosis: A Meta-Analysis. European Spine Journal, 26, 1624-1630. [Google Scholar] [CrossRef] [PubMed]
[17] Tang, W., Chen, S., Liu, J., Liu, C., Wang, Y. and Kang, M. (2018) Investigation of igf1, igf2bp2, and igfbp3 Variants with Lymph Node Status and Esophagogastric Junction Adenocarcinoma Risk. Journal of Cellular Biochemistry, 120, 5510-5518. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, W., Zhang, L.C., Chen, H., Tang, P.F. and Zhang, L.H. (2015) Association between Polymorphisms in Insulin-Like Growth Factor-1 and Risk of Osteoporosis. Genetics and Molecular Research, 14, 7655-7660. [Google Scholar] [CrossRef] [PubMed]
[19] Oh, S.Y., Shin, A., Kim, S., Hwang, J., Hong, S.H., Lee, Y., et al. (2016) Relationship between Insulin-Like Growth Factor Axis Gene Polymorphisms and Clinical Outcome in Advanced Gastric Cancer Patients Treated with Folfox. Oncotarget, 7, 31204-31214. [Google Scholar] [CrossRef] [PubMed]
[20] Wernli, K.J., Newcomb, P.A., Wang, Y., Makar, K.W., Shadman, M., Chia, V.M., et al. (2010) Body Size, IGF and Growth Hormone Polymorphisms, and Colorectal Adenomas and Hyperplastic Polyps. Growth Hormone & IGF Research, 20, 305-309. [Google Scholar] [CrossRef] [PubMed]
[21] Mao, J., Zhuang, G. and Chen, Z. (2017) Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis. Medical Science Monitor, 23, 5892-5898. [Google Scholar] [CrossRef] [PubMed]
[22] Nobakht, H., Mahmoudi, T., Rezamand, G., Tabaeian, S.P., Jeddi, G., Asadi, A., et al. (2022) Association of Rs5742612 Polymorphism in the Promoter Region of igf1 Gene with Nonalcoholic Fatty Liver Disease: A Case-Control Study. Laboratory Medicine, 53, 504-508. [Google Scholar] [CrossRef] [PubMed]
[23] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版) [J]. 传染病信息, 2018, 31(5): 393-402+420.
[24] Song, S.J., Lai, J.C., Wong, G.L., Wong, V.W. and Yip, T.C. (2024) Can We Use Old NAFLD Data under the New MASLD Definition? Journal of Hepatology, 80, e54-e56. [Google Scholar] [CrossRef] [PubMed]
[25] Horita, N. and Kaneko, T. (2015) Genetic Model Selection for a Case-Control Study and a Meta-Analysis. Meta Gene, 5, 1-8. [Google Scholar] [CrossRef] [PubMed]
[26] Wei, S., Wang, L., Evans, P.C. and Xu, S. (2024) NAFLD and NASH: Etiology, Targets and Emerging Therapies. Drug Discovery Today, 29, Article ID: 103910. [Google Scholar] [CrossRef] [PubMed]
[27] Cherubini, A., Casirati, E., Tomasi, M. and Valenti, L. (2021) PNPLA3 as a Therapeutic Target for Fatty Liver Disease: The Evidence to Date. Expert Opinion on Therapeutic Targets, 25, 1033-1043. [Google Scholar] [CrossRef] [PubMed]
[28] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nature Genetics, 40, 1461-1465. [Google Scholar] [CrossRef] [PubMed]
[29] Stefan, N., Häring, H. and Cusi, K. (2019) Non-Alcoholic Fatty Liver Disease: Causes, Diagnosis, Cardiometabolic Consequences, and Treatment Strategies. The Lancet Diabetes & Endocrinology, 7, 313-324. [Google Scholar] [CrossRef] [PubMed]
[30] Yuan, F., Gu, Z., Bi, Y., Yuan, R., Niu, W., Ren, D., et al. (2022) The Association between Rs1260326 with the Risk of NAFLD and the Mediation Effect of Triglyceride on NAFLD in the Elderly Chinese Han Population. Aging, 14, 2736-2747. [Google Scholar] [CrossRef] [PubMed]
[31] Massey, W.J., Varadharajan, V., Banerjee, R., Brown, A.L., Horak, A.J., Hohe, R.C., et al. (2023) MBOAT7-Driven Lysophosphatidylinositol Acylation in Adipocytes Contributes to Systemic Glucose Homeostasis. Journal of Lipid Research, 64, Article ID: 100349. [Google Scholar] [CrossRef] [PubMed]
[32] Werner, H. (2023) The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities. International Journal of Molecular Sciences, 24, Article No. 14882. [Google Scholar] [CrossRef] [PubMed]
[33] Sarmento-Cabral, A., del Rio-Moreno, M., Vazquez-Borrego, M.C., Mahmood, M., Gutierrez-Casado, E., Pelke, N., et al. (2021) GH Directly Inhibits Steatosis and Liver Injury in a Sex-Dependent and Igf1-Independent Manner. Journal of Endocrinology, 248, 31-44. [Google Scholar] [CrossRef] [PubMed]
[34] Yao, Z., Gong, Y., Chen, W., Shao, S., Song, Y., Guo, H., et al. (2023) Upregulation of WDR6 Drives Hepatic De Novo Lipogenesis in Insulin Resistance in Mice. Nature Metabolism, 5, 1706-1725. [Google Scholar] [CrossRef] [PubMed]
[35] Ichikawa, T., Nakao, K., Hamasaki, K., Furukawa, R., Tsuruta, S., Ueda, Y., et al. (2007) Role of Growth Hormone, Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Development of Non-Alcoholic Fatty Liver Disease. Hepatology International, 1, 287-294. [Google Scholar] [CrossRef] [PubMed]
[36] Marques, V., Afonso, M.B., Bierig, N., Duarte-Ramos, F., Santos-Laso, Á., Jimenez-Agüero, R., et al. (2021) Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Frontiers in Medicine, 8, Article ID: 683250. [Google Scholar] [CrossRef] [PubMed]
[37] Sabzikarian, M., Mahmoudi, T., Tabaeian, S.P., Rezamand, G., Asadi, A., Farahani, H., et al. (2020) The Common Variant of Rs6214 in Insulin like Growth Factor 1 (igf1) Gene: A Potential Protective Factor for Non-Alcoholic Fatty Liver Disease. Archives of Physiology and Biochemistry, 129, 10-15. [Google Scholar] [CrossRef] [PubMed]
[38] Mahmoudi, T., Karimi, K., Arkani, M., Farahani, H., Vahedi, M., Dabiri, R., et al. (2014) Resistin-420c>g Promoter Variant and Colorectal Cancer Risk. The International Journal of Biological Markers, 29, 233-238. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, R., Xu, D., Liu, R., Zhao, L., Hu, L. and Wu, P. (2017) Microsatellite and Single Nucleotide Polymorphisms in the Insulin-Like Growth Factor 1 Promoter with Insulin Sensitivity and Insulin Secretion. Medical Science Monitor, 23, 3722-3736. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, J., Chen, X., Zhang, L. and Peng, Y. (2017) igf1 Gene Polymorphisms Associated with Diabetic Retinopathy Risk in Chinese Han Population. Oncotarget, 8, 88034-88042. [Google Scholar] [CrossRef] [PubMed]